Related by context. All words. (Click for frequent words.) 79 alvespimycin 75 ganetespib 75 elotuzumab 75 pertuzumab 75 INCB# [001] 74 obatoclax 74 MGd 73 Azedra 73 YONDELIS 73 bortezomib Velcade R 73 Archexin 73 TELCYTA 73 Phenoptin 72 MAGE A3 ASCI 72 relapsed refractory multiple myeloma 72 phase IIa clinical 72 thymalfasin 72 pomalidomide 72 Sym# 72 forodesine 72 PXD# 71 Aplidin R 71 Amrubicin 71 Phase #b/#a clinical 71 IMA# 71 celgosivir 71 Phase Ib study 71 rNAPc2 71 liposomal doxorubicin 71 Bicifadine 71 Virulizin ® 71 phase IIb clinical 71 liposomal formulation 71 BAY #-# 71 Xanafide 71 Traficet EN 71 CR# vcMMAE 71 Ceflatonin 71 PEG PAL 71 ixabepilone 70 custirsen 70 HuLuc# 70 CoFactor 70 elacytarabine 70 sorafenib Nexavar 70 mapatumumab 70 enzastaurin 70 ponatinib 70 HuMax CD4 70 HuMax EGFr 70 galiximab 70 favorable pharmacokinetic profile 70 sunitinib malate 70 brivaracetam 70 Chemophase 70 vidofludimus 70 dacetuzumab 70 CBLC# 70 CA4P 70 oral prodrug 70 teriflunomide 70 HGS ETR2 70 Tanespimycin 70 axitinib 70 riociguat 70 INCB# [002] 70 PEG SN# 70 ELACYT 70 lintuzumab 70 Symadex 70 Bezielle 70 evaluating tivozanib 70 HGS# 70 ZOLINZA 70 HGS ETR1 70 Phase IIIb clinical 70 Asentar 70 IMC #B 70 BZL# 70 preclinically 69 trabectedin 69 lumiliximab 69 ruxolitinib 69 BRAF inhibitor 69 blinatumomab 69 DAVANAT 69 torezolid phosphate 69 EOquin TM 69 romidepsin 69 AEGR 69 ALN TTR 69 GFT# 69 cannabinor 69 IMGN# 69 EOquin 69 Phase Ib 69 sorafenib tablets 69 iniparib 69 HER2 positive metastatic breast 69 Trofex 69 ularitide 69 LEP ETU 69 PSMA ADC 69 registrational 69 oral FTY# 69 oral ridaforolimus 69 JAK inhibitor 69 R#/MEM # 69 PS# [001] 69 CCX# 69 radiation sensitizer 69 neratinib 69 histone deacetylase HDAC inhibitor 69 TELINTRA 69 efficacy tolerability 69 gemcitabine Gemzar ® 69 Tyrima 69 Phase Ib clinical 69 IMC A# 69 T DM1 69 vandetanib 69 Pertuzumab 69 Apoptone 69 OncoVEX GM CSF 69 fosbretabulin 69 GAMMAGARD 68 Cloretazine R VNP#M 68 docetaxel Taxotere R 68 eniluracil 68 KRN# 68 CIMZIA TM 68 reslizumab 68 Capesaris 68 TACI Ig 68 paclitaxel Taxol ® 68 Alocrest 68 Pimavanserin 68 AP# [003] 68 Cloretazine ® 68 TKM ApoB 68 Zolinza 68 sapacitabine 68 APOPTONE 68 Tarceva TM 68 metaglidasen 68 BRIM2 68 OXi# 68 EFAPROXYN 68 tezampanel 68 ZACTIMA 68 Ambrisentan 68 phase IIb 68 MGCD# [001] 68 tamibarotene 68 Ceplene/IL-2 68 XmAb# 68 palifosfamide 68 orally administered inhibitor 68 Trastuzumab 68 farletuzumab 68 relapsed MM 68 Phase #b/#a 68 Dacogen injection 68 AZILECT R 68 metastatic hormone refractory 68 Aplidin 68 Aflibercept 68 EndoTAG TM -1 68 regorafenib 68 receptor tyrosine kinase inhibitor 68 Bortezomib 68 tesmilifene 68 trastuzumab DM1 68 vascular disrupting agent 68 phase IIb trial 68 PF # [001] 68 placebo controlled clinical 68 cilengitide 68 inhibitor RG# 68 ocrelizumab 68 vorinostat 68 MyVax R 68 novel VDA molecule 68 refractory chronic lymphocytic 68 PROSTVAC TM 68 AAG geldanamycin analog 68 Tasimelteon 68 deforolimus 68 Phase 2a trial 68 viral kinetics 68 vosaroxin 68 crizotinib PF # 68 Vandetanib 67 Amigal 67 AQ4N 67 AEG# 67 PHX# 67 Phase 1b trial 67 ACAPODENE 67 Panzem R NCD 67 GALNS 67 delafloxacin 67 Marqibo 67 ATL# [001] 67 phase Ib 67 bevacizumab Avastin ® 67 Panzem R 67 FOLOTYN ® 67 TLK# 67 atrasentan 67 seliciclib 67 adecatumumab 67 cetuximab Erbitux ® 67 recurrent glioblastoma multiforme 67 Imprime PGG 67 diabetic neuropathic pain 67 BIBW 67 Phase #/#a 67 Taxotere ® 67 belinostat 67 dasatinib Sprycel ® 67 Plicera 67 APTIVUS 67 trastuzumab Herceptin 67 rALLy clinical trial 67 pan HDAC inhibitor 67 Proxinium TM 67 cediranib 67 nucleoside analog 67 alemtuzumab Campath 67 erlotinib Tarceva ® 67 tezampanel NGX# 67 nab paclitaxel 67 docetaxel Taxotere ® 67 Doxil ® 67 LHRH antagonists 67 CRx 67 interferon gamma 1b 67 virus HCV protease inhibitor 67 MGN# 67 perifosine 67 mertansine 67 Panzem NCD 67 Telintra 67 lapatinib Tykerb 67 docetaxel Taxotere 67 GW# [003] 67 Phase 2b clinical 67 OvaRex ® MAb 67 HCD# [002] 67 Zenvia ™ 67 vicriviroc 67 standard chemotherapy regimen 67 mycophenolate mofetil 67 ZYBRESTAT 67 mRCC 67 Panitumumab 67 refractory AML 67 CTAP# Capsules 67 STRIDE PD 67 anti EGFR antibody 67 EndoTAGTM 1 67 posaconazole 67 JAK2 inhibitor 67 tramiprosate Alzhemed TM 67 DOXIL 67 Abiraterone acetate 67 SAR# [004] 67 Golimumab 67 Phase IIa trials 67 CEQ# 67 dosage regimens 67 UPLYSO 67 RGB # 67 AZILECT ® 67 Triolex 67 ofatumumab 67 phase IIa 67 carfilzomib 67 CIMZIA ™ 67 Targretin 67 eltrombopag 67 APTIVUS r 67 selective androgen receptor modulator 67 TYKERB 67 ONCONASE 67 refractory multiple myeloma 67 relapsed multiple myeloma 67 Allovectin 7 67 Saforis 67 castrate resistant prostate cancer 67 Arranon 67 Intravenous CP 67 imetelstat 67 heavily pretreated 67 CYT# potent vascular disrupting 67 Phase Ib II 67 atacicept 67 amrubicin 67 PRT# 66 Cloretazine R 66 glufosfamide 66 LibiGel ® 66 Phase IIa clinical 66 picoplatin 66 EVIZON 66 PI3K/Akt pathway inhibitor 66 TOCOSOL Paclitaxel 66 ONCONASE R 66 APEX PD 66 GSK# [001] 66 ILLUMINATE 66 azacitidine 66 trastuzumab DM1 T DM1 66 imatinib Gleevec ® 66 budesonide foam 66 ISIS # 66 Elagolix 66 Alzhemed TM 66 ARIKACE ™ 66 SNT MC# 66 erlotinib Tarceva 66 Hsp# inhibitor 66 Dasatinib 66 valopicitabine 66 AzaSite Plus 66 LY# [003] 66 HuMax CD# 66 huC# DM4 66 temsirolimus 66 Zerenex 66 PANVAC VF 66 HspE7 66 PRTX 66 GRN#L 66 IL# PE#QQR 66 Onalta ™ 66 RSR# 66 DCVax R 66 tipranavir 66 confirmatory Phase III 66 L BLP# 66 CANCIDAS 66 capecitabine Xeloda 66 Phase Ib clinical trials 66 zalutumumab 66 Cloretazine 66 IRX 2 66 Phase III randomized controlled 66 iclaprim 66 RG# [001] 66 Interferon beta 1a 66 dasatinib Sprycel 66 subcutaneous formulation 66 dexpramipexole 66 CORT # 66 Fibrillex TM 66 pharmacokinetic PK 66 TBC# 66 phase IIb study 66 PSN# [002] 66 pharmacodynamic properties 66 pharmacodynamic profile 66 QVA# 66 Telatinib 66 ISENTRESS 66 panitumumab Vectibix 66 paclitaxel Taxol 66 otelixizumab 66 Fx #A 66 Stedivaze 66 relapsed ovarian cancer 66 MoxDuo IR 66 Campath alemtuzumab 66 NP2 Enkephalin 66 Allovectin 7 ® 66 veltuzumab 66 LymphoStat B belimumab 66 epothilone 66 Natalizumab 66 OMNARIS HFA 66 pharmacokinetic PK study 66 selective modulator 66 6R BH4 66 Jevtana 66 BCX# 66 DermaVir Patch 66 MDV# 66 Synavive 66 refractory acute myeloid 66 TOLAMBA 66 Nanobody 66 personalized immunotherapy 66 demonstrated antitumor activity 66 INT# [002] 66 Phase 1a clinical 66 Safinamide 66 follicular NHL 66 targeted radiotherapeutic 66 Amplimexon 66 TRO# 66 Cetrorelix 66 entinostat 66 BrachySil TM 66 AVASTIN 66 rilonacept 66 varespladib 66 CLORETAZINE TM VNP#M 66 gefitinib Iressa 66 Taxotere R 66 clevidipine 66 afatinib 66 trastuzumab Herceptin R 66 myelofibrosis 66 Rebif ® 66 miconazole Lauriad ® 66 ADVEXIN 66 ProSavin 66 oral deforolimus 66 SCH # 66 teduglutide 66 SUTENT ® 66 darapladib 66 FASLODEX 66 DXL# 66 systemic RNAi therapeutic 66 Exelixis XL# 66 tigecycline 66 Ostarine 66 mg/m2 dose 66 adalimumab Humira 66 infusional 5-FU/LV 66 PREOS 66 Benlysta belimumab 66 sargramostim 66 R#/MEM 66 ZYBRESTAT fosbretabulin 66 Quinamed 66 Vilazodone 66 Zybrestat 66 Phase 2a clinical 66 ADAGIO study 66 pegylated liposomal doxorubicin 66 talactoferrin 66 MEK inhibitors 66 R roscovitine 66 pharmacodynamic PD 66 Anturol TM 66 somatostatin analogue 66 LY# [002] 66 tafamidis 66 recurrent NSCLC 66 Panzem 66 RoACTEMRA 66 aleglitazar 66 Phase IIa trial 66 ENMD # 66 Dapagliflozin 66 DACH platinum 65 thetreatment 65 PLK1 SNALP 65 orBec 65 Dalbavancin 65 TREANDA 65 IIa trial 65 NGX# 65 orally bioavailable 65 SUTENT 65 decitabine 65 Viramidine 65 Solazed TM 65 OHR/AVR# 65 Advaxis Phase 65 XYOTAX TM 65 pharmacodynamic 65 RLY# 65 Virulizin R 65 metastatic renal cell carcinoma 65 Exelixis compounds 65 lorvotuzumab mertansine 65 lenalidomide dexamethasone 65 active comparator 65 Diamyd ® 65 investigational humanized monoclonal antibody 65 Zelrix 65 pralatrexate 65 ELND# 65 cariprazine 65 rindopepimut 65 molecularly targeted 65 CINQUIL 65 bendamustine 65 sunitinib 65 Onrigin 65 OPAXIO 65 motesanib diphosphate 65 systemic anaplastic large 65 Phase IIb clinical 65 ISTODAX 65 sipuleucel T 65 registrational trial 65 hA# 65 Perifosine 65 Phase #/#a trial 65 RhuDex ® 65 cutaneous T cell 65 proteasome inhibitor bortezomib 65 HQK 65 oral rivaroxaban 65 tocilizumab 65 pain palliation 65 PROMACTA 65 Tamibarotene 65 antiangiogenic therapy 65 dose cohorts 65 BAL# [002] 65 vemurafenib 65 Icatibant 65 gemcitabine carboplatin 65 apremilast 65 Azedra TM 65 Serdaxin 65 LAF# 65 Blinatumomab 65 Aptivus 65 ALN PCS 65 Phase 1b 65 antiangiogenic agents 65 dirucotide 65 Phase 1b clinical 65 MAA submission 65 Urocidin 65 refractory gout 65 oral Xeloda 65 Onconase 65 OncoVEX 65 anti angiogenic agents 65 Hsp# inhibition 65 FOLFOX6 chemotherapy regimen 65 CRLX# 65 PEG Interferon lambda 65 OMAPRO 65 metastatic CRC 65 panitumumab 65 Troxatyl 65 CINTREDEKIN BESUDOTOX 65 PEGylated interferon beta 1a 65 tarenflurbil 65 cMET 65 XL# XL# XL# 65 vinorelbine 65 ongoing Phase 1b 65 opioid induced bowel dysfunction 65 GATTEX ® 65 Zemplar Capsules 65 GAP #B# 65 Velcade bortezomib 65 Phase IIb trials 65 omacetaxine mepesuccinate 65 darinaparsin ZIO 65 HCV protease inhibitor 65 taxane refractory 65 rFIXFc 65 RhuDex TM 65 KNS # 65 paclitaxel poliglumex 65 ALN TTR# 65 Telcyta 65 dimebon 65 PrevOnco ™ 65 alvimopan 65 EGS# 65 trastuzumab Herceptin ® 65 Plenaxis TM 65 myelofibrosis polycythemia vera 65 anticancer compound 65 convenient dosing regimens 65 Neulasta ® 65 initiate Phase 1b 65 VNP#M 65 ELOXATIN 65 dose cohort 65 Insegia 65 bortezomib 65 Pemetrexed 65 Ophena TM 65 Randomized Phase 65 triphendiol 65 pharmacodynamic effects 65 biologic therapy 65 FavId 65 ATL/TV# 65 Aurexis 65 fluoropyrimidine 65 Fludara ® 65 metastatic castration resistant 65 Inhalation Solution 65 DDP# 65 chemotherapeutic drug 65 huN# DM1 65 TORISEL 65 cell lymphoma CTCL 65 IRESSA 65 Pharmacokinetics PK 65 CHOP chemotherapy 65 Pivotal Phase III 65 ostarine 65 XL# SAR# 65 TRIOLEX 65 LUX Lung 65 radezolid 65 Targretin capsules 65 baminercept 65 Laquinimod 65 BNC# 65 dextromethorphan quinidine 65 sorafenib Nexavar ® 65 investigational compound 65 LymphoStat B 65 CYT# 65 Cotara 65 vascular disrupting agents 65 Phase IIb III 65 Gemzar ® 65 gemcitabine Gemzar 65 mTOR inhibitor 65 EDEMA3 65 depsipeptide 65 Intervention Effectiveness 65 myelofibrosis MF 65 leukemia AML 65 ALGRX 65 Sprycel dasatinib 65 proteasome inhibitor 65 pegfilgrastim 65 Evoltra ® 65 dose escalation phase 65 refractory CLL 65 velafermin 65 oral picoplatin 65 gemcitabine chemotherapy 65 assessing T DM1 65 Solazed 65 Combo Stent 65 protease inhibitor PI 65 figitumumab 65 Phase IIb clinical trials 65 PD LID 65 Tezampanel 65 evaluating REVLIMID 65 IAP inhibitors 65 davunetide intranasal AL 65 NUVIGIL 65 acute coronary syndromes ACS 65 docetaxel chemotherapy 65 lomitapide 65 CIMZIA TM certolizumab pegol 65 #mg/m# [001] 65 S/GSK# 65 NVA# 65 Actimmune ® 65 ORENCIA ® 65 polycythemia vera essential thrombocythemia 65 TG# [001] 65 Seliciclib 65 recurrent GBM 64 SRT# [003] 64 Tavocept 64 Xcytrin R 64 MAXY G# 64 trastuzumab emtansine T DM1 64 cetuximab Erbitux 64 Corlux 64 lupus nephritis 64 EP #R 64 XL# XL# XL# XL# 64 multicentre randomized 64 viral kinetic 64 ThGRF 64 Azacitidine 64 phase 2a 64 eprotirome 64 Elocalcitol 64 CD# antibody [001] 64 platinum refractory 64 Mitoxantrone 64 MAP# 64 Phase 2b trial 64 histone deacetylase inhibitor 64 lintuzumab SGN 64 bosutinib 64 investigational monoclonal antibody 64 neoadjuvant 64 PREZISTA r 64 VELCADE melphalan 64 BrachySil 64 oxypurinol 64 JAK2 inhibitors 64 placebo controlled Phase 64 cisplatin gemcitabine 64 melphalan prednisone 64 metastatic HRPC 64 Radezolid 64 intravenous cyclophosphamide 64 Personalized Immunotherapy 64 motesanib 64 ThermoDox R 64 safinamide 64 INC# 64 NATRECOR ® 64 PROVENGE sipuleucel T 64 OMP #M# 64 Phase 1b clinical trials 64 boosted protease inhibitor 64 Cimzia TM 64 Phase IIIb 64 anti amnesic 64 Triapine R 64 TPI ASM8 64 Fulvestrant 64 GLPG# 64 cabazitaxel 64 Romidepsin 64 diarrhea predominant irritable 64 afamelanotide 64 Fludara 64 Pyridorin 64 secondary efficacy endpoints 64 Zenvia TM 64 YONDELIS R 64 Epratuzumab 64 Annamycin 64 ACTEMRA TM 64 multicenter Phase II 64 alpha 2a 64 dose escalation clinical 64 photoprotective drug 64 low dose cytarabine 64 Nexavar ® 64 anti leukemic 64 metastatic castrate resistant 64 IIb clinical trial 64 VEGF Trap 64 evaluating satraplatin 64 Prodarsan 64 catheter occlusion 64 double blinded placebo 64 aflibercept 64 ORENCIA R 64 novel anticancer 64 relapsed SCLC 64 bafetinib 64 pharmacodynamics PD 64 Carfilzomib 64 cabozantinib 64 Androxal TM 64 TASQ 64 Restanza 64 cetuximab Erbitux R 64 multicenter Phase III 64 Noxafil 64 DCCR 64 ProLindac 64 Oral NKTR 64 lesinurad 64 endothelin receptor antagonists 64 investigational protease inhibitor 64 Aptivus ® 64 tremelimumab 64 phase IIb III 64 metastatic RCC 64 EGFR antibodies 64 gemcitabine cisplatin 64 Rigel R# 64 ToGA 64 Hsp# inhibitor tanespimycin 64 MORAb 64 Daclizumab 64 CYCLOSET 64 carboplatin paclitaxel 64 HCV protease inhibitors 64 bardoxolone methyl 64 TYZEKA 64 LEVADEX ™ 64 5 FU leucovorin 64 chemotherapy induced neutropenia 64 MEND CABG 64 Pirfenidone 64 randomized Phase IIb 64 PrevOnco 64 acyclovir Lauriad R 64 castration resistant prostate cancer 64 JAK inhibitors 64 indibulin 64 ulimorelin 64 INTELENCE 64 INS# [001] 64 MYDICAR 64 Treanda 64 NATRECOR R 64 KRAS status 64 olaparib 64 Ixempra 64 ofatumumab HuMax CD# 64 BR.# 64 metastatic malignant 64 INCB# [003] 64 FOLPI 64 Acute Ischemic Stroke 64 favorable tolerability 64 pegylated interferons 64 blinded randomized placebo controlled 64 ThermoDox ® 64 Stimuvax R 64 samalizumab 64 AVONEX ® 64 bevacizumab Avastin 64 OncoVex 64 ZK EPO 64 lymphoid malignancies 64 Prestara 64 bosentan 64 CYC# 64 vilazodone 64 orally inhaled migraine 64 Betaferon ® 64 volociximab 64 urocortin 2 64 visilizumab 64 Serdaxin ® 64 ADVANCE PD 64 MYLOTARG 64 Xeloda ® 64 seliciclib CYC# 64 gastrointestinal stromal tumors GIST 64 ataluren 64 plasma kallikrein inhibitor 64 Naproxcinod 64 Cardio Vascu Grow 64 Spiegelmer ® 64 zanolimumab 64 relapsed MCL 64 Clolar ® 64 immunotherapeutic vaccine 64 NOX E# 64 cancer immunotherapies 64 PNP inhibitor 64 oxymorphone ER 64 prucalopride 64 bicifadine 64 efalizumab 64 cytotoxic chemotherapy 64 thalidomide Thalomid 64 Irinotecan 64 TG# [003] 64 Atiprimod 64 temsirolimus Torisel ® 64 PCK# 64 CCR5 inhibitors 64 Genz # 64 chlorambucil 64 Phase 2b study 64 romiplostim 64 edoxaban 64 Eribulin 64 PDX pralatrexate 64 paclitaxel Taxol R 64 preclinical efficacy 64 MYCAMINE 64 investigational therapies 64 Glufosfamide 64 ZYBRESTAT TM 64 ritonavir boosted danoprevir 64 Squalamine 64 cystinosis patients 64 ATACAND 64 K ras mutations 64 DPX Survivac 64 UVIDEM 64 Gleevec resistant 64 MERLIN TIMI 64 sunitinib Sutent ® 64 severe hypercholesterolemia 64 alkylating agent 64 Trastuzumab DM1 64 noninferiority 64 AeroLEF TM 64 oral methylnaltrexone 64 canakinumab 64 dyskinesia PD LID 64 epigenetic therapies 64 Avanafil 64 randomized Phase III 64 Peginterferon 64 Cimzia ® certolizumab pegol 64 IgG1 antibody 64 COPEGUS 64 pramlintide metreleptin combination 64 Hycamtin 64 antibody MAb 64 #D#C# 64 Pivotal Phase 64 Linjeta TM 64 REMINYL ® 64 Copegus ribavirin 63 ACTEMRA 63 tolvaptan 63 trabedersen 63 GLYX 63 nilotinib Tasigna ® 63 CaPre TM 63 BLA filing 63 antiangiogenic agent 63 refractory Hodgkin lymphoma 63 VAPRISOL 63 Debio 63 NEUMUNE 63 MEK inhibitor RDEA# 63 ara C 63 Factor VIIa 63 bortezomib Velcade 63 EGFR HER2 63 BENLYSTA ® 63 maximally tolerated dose 63 TAXOTERE R 63 retaspimycin 63 investigational hepatitis C 63 Neuvenge 63 Phase III clinical 63 BCIRG 63 ASONEP 63 ospemifene 63 Civacir 63 non nucleoside HCV 63 Mipomersen 63 Tarvacin TM 63 FOLOTYN 63 MEK inhibitor 63 TEMODAL 63 PDE4 inhibitor 63 DAPT 63 Vidaza ® 63 antitumor effect 63 darinaparsin 63 Interferon alpha 63 pharmacokinetic equivalence 63 liposomal amphotericin B 63 Mylotarg 63 masitinib 63 glatiramer acetate 63 Zoraxel 63 ritonavir boosted 63 ganaxolone 63 IAP inhibitor 63 myeloproliferative disorders 63 refractory prostate cancer 63 oral Azacitidine 63 tolerability pharmacokinetics 63 Fodosine 63 palifermin 63 noninfectious uveitis 63 XL# XL# 63 tivozanib 63 adipiplon 63 BRIM3 63 GOUT 63 FOLFIRI 63 clinical endpoints 63 refractory colorectal cancer 63 dose escalation trial 63 REOLYSIN ® 63 immunotherapeutic agent 63 uric acid lowering 63 IIIa inhibitor 63 Firazyr 63 dose escalation Phase 63 indolent NHL 63 vinca alkaloid 63 CD3 monoclonal antibody 63 ridaforolimus 63 SPRYCEL ® 63 tesetaxel 63 Vidaza azacitidine 63 corticosteroid dexamethasone 63 Revlimid lenalidomide 63 RIGScan CR 63 Revimmune 63 AVADO 63 ancrod 63 desvenlafaxine succinate 63 XL# anticancer compounds 63 Aryplase 63 Vicinium TM 63 pharmacokinetic interactions 63 Vectibix panitumumab 63 Azedra ™ 63 Ranolazine 63 ONTARGET 63 plus prednisone